By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Agomelatine

Agomelatine

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
4 Min Read
SHARE
3 min read|586 words

What is Agomelatine?

Agomelatine is an atypical antidepressant medication that belongs to a unique class of drugs called melatonergic antidepressants. It is primarily prescribed for the treatment of major depressive disorder in adults. Unlike traditional antidepressants that primarily target serotonin or norepinephrine systems, agomelatine works through a novel mechanism involving melatonin and serotonin receptors.

Uses

Agomelatine is approved and used for several conditions:

  • Major depressive disorder: The primary indication for agomelatine, particularly effective in patients with sleep disturbances and circadian rhythm disruption
  • Seasonal affective disorder: May be prescribed for depression that occurs during specific seasons, typically winter months
  • Anxiety disorders: Sometimes used off-label for generalized anxiety disorder, particularly when accompanied by depression
  • Sleep disorders in depression: Specifically helpful for patients with depression who experience significant sleep pattern disruptions
  • Bipolar depression: Occasionally used as an adjunct treatment in bipolar disorder during depressive episodes

How it works

Agomelatine works through a dual mechanism that sets it apart from other antidepressants. It acts as an agonist at melatonin MT1 and MT2 receptors, helping to regulate circadian rhythms and sleep-wake cycles. Simultaneously, it blocks serotonin 5-HT2C receptors, which indirectly increases the release of dopamine and norepinephrine in the brain’s frontal cortex, contributing to its antidepressant effects.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Headache
  • Dizziness
  • Drowsiness or fatigue
  • Nausea
  • Insomnia or sleep disturbances
  • Dry mouth
  • Diarrhea
  • Sweating

Serious side effects to watch for:

  • Liver damage or hepatitis (elevated liver enzymes)
  • Severe allergic reactions
  • Suicidal thoughts or behavior, particularly in young adults
  • Severe mood changes or manic episodes
  • Abnormal bleeding or bruising

Warnings and precautions

  • Liver function monitoring: Regular liver function tests are required due to the risk of hepatotoxicity, particularly during the first few months of treatment
  • Avoid in liver disease: Patients with existing liver problems, including cirrhosis or hepatic impairment, should not use agomelatine
  • Pregnancy and breastfeeding: Use during pregnancy should be carefully evaluated, and the medication may pass into breast milk
  • Suicide risk: Like all antidepressants, agomelatine may increase suicidal thoughts in patients under 25 years old, especially during the first few weeks of treatment
  • Elderly patients: Dose adjustments may be necessary in older adults due to increased sensitivity and slower metabolism

Interactions

Agomelatine can interact with several medications and substances:

  • CYP1A2 inhibitors (fluvoxamine, ciprofloxacin): Can significantly increase agomelatine levels, potentially leading to toxicity
  • Smoking cessation: Quitting smoking can increase agomelatine levels since tobacco smoke induces CYP1A2 enzymes that metabolize the drug
  • Oral contraceptives: Birth control pills may increase agomelatine levels by inhibiting its metabolism
  • Warfarin and anticoagulants: May increase bleeding risk when combined with agomelatine
  • Other antidepressants: Combination with SSRIs or SNRIs requires careful monitoring for serotonin syndrome
  • Alcohol: Can enhance drowsiness and may worsen liver-related side effects
  • St. John’s Wort: May reduce agomelatine effectiveness by increasing its metabolism
  • Benzodiazepines: Combined sedative effects may cause excessive drowsiness

Check interactions with the GMJ Interaction Checker

Dosage

The typical starting dose for adults is 25 mg taken once daily at bedtime. If insufficient response is observed after two weeks, the dose may be increased to 50 mg once daily at bedtime. The medication should be taken without food, as food can significantly reduce its absorption. Liver function should be monitored before starting treatment and periodically thereafter. Dosage should always be determined and adjusted by a healthcare provider based on individual patient response and tolerability.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Agomelatine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/agomelatine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
FDA’s Pazdur Calls for Agency Restructuring Amid China Competition and Internal Upheaval

FDA's Rick Pazdur calls for fundamental agency restructuring following internal disruption, citing…

Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Oxcarbazepine

By
Prof. Giorgi Pkhakadze
02/06/2026

Cimetidine

By
Prof. Giorgi Pkhakadze
02/06/2026

Ritonavir

By
Prof. Giorgi Pkhakadze
02/06/2026

Theophylline

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up